Introduction: SSRs are therapeutic targets for the somatostatin analogues in treatment of gasrtroenteropancreatic neuroendocrine tumors (GEP-NET).
Aim(s): To compare the expression rate of SSR types 1-3, 5 in different grade and localization GEP-NETs
Materials and methods: We examined immunohistochemicaly the expression of SSR1-3,5 in 126 GEP-NETs: 86 tumors of the pancreas (pNET), 40 of the intestine (inNET), 89 NET were functioning. To determine the SSR2,5 rabbit monoclonal antibodies were used. We considered expression of SSRs with an intensity of 2-3+ in not less than 50% of tumor cells
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: MD Larisa Gurevich
To read results and conclusion, please login ...
Further abstracts you may be interested in